Temporary left ventricular assist device for complete recovery from reversible acute heart failure due to tumor necrosis factor-α inhibitor

We present the case of a 38-year-old woman with symptoms of acute heart failure (HF). In the previous months, she received tumor necrosis factor (TNF)-α inhibitors for the treatment of arthritis secondary to Crohn’s disease. She initially received etanercept (Enbrel) for nearly 1 year and subsequent...

Full description

Saved in:
Bibliographic Details
Published in:Anatolian journal of cardiology 2019-07, Vol.22 (1), p.46-48
Main Authors: Soucy-Giguere, Marie-Camille, Charbonneau, Éric, Cinq Mars, Alexandre, Dubois, Michelle, Sénéchal, Mario
Format: Article
Language:English
Subjects:
Adult
Arthritis - drug therapy
Arthritis - etiology
Biopsy
Blood pressure
Cardiac arrhythmia
Cardiology
Cardiomyocytes
Cardiomyopathy
Cardiomyopathy, Dilated - complications
Cardiomyopathy, Dilated - diagnosis
Cardiomyopathy, Dilated - drug therapy
Cardiotonic Agents - therapeutic use
Case Reports
Clinical deterioration
Crohn Disease - complications
Crohn's disease
Ejection fraction
Electrocardiography
Etanercept - therapeutic use
Family medical history
Female
Furosemide - therapeutic use
Heart attacks
Heart failure
Heart Failure - chemically induced
Heart Failure - therapy
Heart-Assist Devices
Humans
Infliximab - adverse effects
Infliximab - therapeutic use
lvad
Milrinone - therapeutic use
Monoclonal antibodies
Necrosis
NMR
Nuclear magnetic resonance
Patients
Pulmonary arteries
Rheumatoid arthritis
tnf-alpha inhibitors
toxicity
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor necrosis factor-TNF
Ultrasonic imaging
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 48
container_issue 1
container_start_page 46
container_title Anatolian journal of cardiology
container_volume 22
creator Soucy-Giguere, Marie-Camille
Charbonneau, Éric
Cinq Mars, Alexandre
Dubois, Michelle
Sénéchal, Mario
description We present the case of a 38-year-old woman with symptoms of acute heart failure (HF). In the previous months, she received tumor necrosis factor (TNF)-α inhibitors for the treatment of arthritis secondary to Crohn’s disease. She initially received etanercept (Enbrel) for nearly 1 year and subsequently received infliximab (Remicade) for 6 months. Echocardiograms following the etanercept therapy were normal. Since her disease did not respond well to etanercept, she received 16 treatments of infliximab, at the end of which HF symptoms developed, with rapid clinical deterioration. Her echocardiogram demonstrated dilated cardiomyopathy with severe biventricular dysfunction and left ventricular ejection fraction (LVEF) and right ventricular ejection fraction (RVEF)
doi_str_mv 10.14744/AnatolJCardiol.2019.67124
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_658e251b42be43b9ab004e0477d0f771</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_658e251b42be43b9ab004e0477d0f771</doaj_id><sourcerecordid>2257692405</sourcerecordid><originalsourceid>FETCH-LOGICAL-d327t-4abfd12cd55a8d868d06a53a4fa99e54660a120be788f64668f3163d831dec2b3</originalsourceid><addsrcrecordid>eNpVkUtuFDEQhlsIRKKQKyAL1j341Xb3Bika8QiKxCasW2W7nPHI3R7c7pG4A5fhIpwJDwkRWbmqfvur-stN84bRDZNayndXM5QUv2whu5DihlM2bJRmXD5rzjmTQ8u5Zs8fYyXOmstl2VNKmRY9Y-plcyYYV1Ipet78vMXpkDLkHySiL-SIc8nBrhEygWUJSyEOj8Ei8SkTm6ZDxIIko01HrI98TlPNarwEE5GAXau8Q8iFeAhxzUjciqQkUtapIma0OVVuVW1Juf39i4R5F0yoyavmhYe44OXDedF8-_jhdvu5vfn66Xp7ddM6wXVpJRjvGLeu66B3veodVdAJkB6GAbuTMWCcGtR9708-ey-YEq4XzKHlRlw01_dcl2A_HnKYqv8xQRj_FlK-G-v8wUYcVdcj75iR3KAUZgBDqUQqtXbUa80q6_0967CaCZ097Q_iE-hTZQ678S4dxzqW4IxXwNsHQE7fV1zKuE9rnqv_kfNOq4FL2tVbr_9v88j_95PiD3xfqbU</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2257692405</pqid></control><display><type>article</type><title>Temporary left ventricular assist device for complete recovery from reversible acute heart failure due to tumor necrosis factor-α inhibitor</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Soucy-Giguere, Marie-Camille ; Charbonneau, Éric ; Cinq Mars, Alexandre ; Dubois, Michelle ; Sénéchal, Mario</creator><creatorcontrib>Soucy-Giguere, Marie-Camille ; Charbonneau, Éric ; Cinq Mars, Alexandre ; Dubois, Michelle ; Sénéchal, Mario</creatorcontrib><description>We present the case of a 38-year-old woman with symptoms of acute heart failure (HF). In the previous months, she received tumor necrosis factor (TNF)-α inhibitors for the treatment of arthritis secondary to Crohn’s disease. She initially received etanercept (Enbrel) for nearly 1 year and subsequently received infliximab (Remicade) for 6 months. Echocardiograms following the etanercept therapy were normal. Since her disease did not respond well to etanercept, she received 16 treatments of infliximab, at the end of which HF symptoms developed, with rapid clinical deterioration. Her echocardiogram demonstrated dilated cardiomyopathy with severe biventricular dysfunction and left ventricular ejection fraction (LVEF) and right ventricular ejection fraction (RVEF) &lt;20% with severe functional mitral and tricuspid regurgitation. Her extensive diagnostic work-up, including pathological examination of endomyocardial biopsy, was normal. Despite optimal treatment of HF, her status did not improve, and a left ventricular assist device (LVAD, HeartMate II) was implanted. The evolution was unremarkable, and she rapidly recovered in the following months, with LVEF reaching ≥45%. Based on the patient’s clinical improvement and LVEF recuperation, LVAD was removed. Her functional status and LVEF remained stable after LVAD explantation. Therefore, the very probable etiology of the precipitated HF was infliximab toxicity.</description><identifier>ISSN: 2149-2263</identifier><identifier>EISSN: 2149-2271</identifier><identifier>EISSN: 2149-2263</identifier><identifier>DOI: 10.14744/AnatolJCardiol.2019.67124</identifier><identifier>PMID: 31264660</identifier><language>eng</language><publisher>Turkey: Kare Publishing</publisher><subject>Adult ; Arthritis - drug therapy ; Arthritis - etiology ; Biopsy ; Blood pressure ; Cardiac arrhythmia ; Cardiology ; Cardiomyocytes ; Cardiomyopathy ; Cardiomyopathy, Dilated - complications ; Cardiomyopathy, Dilated - diagnosis ; Cardiomyopathy, Dilated - drug therapy ; Cardiotonic Agents - therapeutic use ; Case Reports ; Clinical deterioration ; Crohn Disease - complications ; Crohn's disease ; Ejection fraction ; Electrocardiography ; Etanercept - therapeutic use ; Family medical history ; Female ; Furosemide - therapeutic use ; Heart attacks ; Heart failure ; Heart Failure - chemically induced ; Heart Failure - therapy ; Heart-Assist Devices ; Humans ; Infliximab - adverse effects ; Infliximab - therapeutic use ; lvad ; Milrinone - therapeutic use ; Monoclonal antibodies ; Necrosis ; NMR ; Nuclear magnetic resonance ; Patients ; Pulmonary arteries ; Rheumatoid arthritis ; tnf-alpha inhibitors ; toxicity ; Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors ; Tumor necrosis factor-TNF ; Ultrasonic imaging</subject><ispartof>Anatolian journal of cardiology, 2019-07, Vol.22 (1), p.46-48</ispartof><rights>2019. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at http://www.anakarder.com/Copyright</rights><rights>Copyright: © 2019 Turkish Society of Cardiology 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2257692405/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2257692405?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31264660$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soucy-Giguere, Marie-Camille</creatorcontrib><creatorcontrib>Charbonneau, Éric</creatorcontrib><creatorcontrib>Cinq Mars, Alexandre</creatorcontrib><creatorcontrib>Dubois, Michelle</creatorcontrib><creatorcontrib>Sénéchal, Mario</creatorcontrib><title>Temporary left ventricular assist device for complete recovery from reversible acute heart failure due to tumor necrosis factor-α inhibitor</title><title>Anatolian journal of cardiology</title><addtitle>Anatol J Cardiol</addtitle><description>We present the case of a 38-year-old woman with symptoms of acute heart failure (HF). In the previous months, she received tumor necrosis factor (TNF)-α inhibitors for the treatment of arthritis secondary to Crohn’s disease. She initially received etanercept (Enbrel) for nearly 1 year and subsequently received infliximab (Remicade) for 6 months. Echocardiograms following the etanercept therapy were normal. Since her disease did not respond well to etanercept, she received 16 treatments of infliximab, at the end of which HF symptoms developed, with rapid clinical deterioration. Her echocardiogram demonstrated dilated cardiomyopathy with severe biventricular dysfunction and left ventricular ejection fraction (LVEF) and right ventricular ejection fraction (RVEF) &lt;20% with severe functional mitral and tricuspid regurgitation. Her extensive diagnostic work-up, including pathological examination of endomyocardial biopsy, was normal. Despite optimal treatment of HF, her status did not improve, and a left ventricular assist device (LVAD, HeartMate II) was implanted. The evolution was unremarkable, and she rapidly recovered in the following months, with LVEF reaching ≥45%. Based on the patient’s clinical improvement and LVEF recuperation, LVAD was removed. Her functional status and LVEF remained stable after LVAD explantation. Therefore, the very probable etiology of the precipitated HF was infliximab toxicity.</description><subject>Adult</subject><subject>Arthritis - drug therapy</subject><subject>Arthritis - etiology</subject><subject>Biopsy</subject><subject>Blood pressure</subject><subject>Cardiac arrhythmia</subject><subject>Cardiology</subject><subject>Cardiomyocytes</subject><subject>Cardiomyopathy</subject><subject>Cardiomyopathy, Dilated - complications</subject><subject>Cardiomyopathy, Dilated - diagnosis</subject><subject>Cardiomyopathy, Dilated - drug therapy</subject><subject>Cardiotonic Agents - therapeutic use</subject><subject>Case Reports</subject><subject>Clinical deterioration</subject><subject>Crohn Disease - complications</subject><subject>Crohn's disease</subject><subject>Ejection fraction</subject><subject>Electrocardiography</subject><subject>Etanercept - therapeutic use</subject><subject>Family medical history</subject><subject>Female</subject><subject>Furosemide - therapeutic use</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Heart Failure - chemically induced</subject><subject>Heart Failure - therapy</subject><subject>Heart-Assist Devices</subject><subject>Humans</subject><subject>Infliximab - adverse effects</subject><subject>Infliximab - therapeutic use</subject><subject>lvad</subject><subject>Milrinone - therapeutic use</subject><subject>Monoclonal antibodies</subject><subject>Necrosis</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Patients</subject><subject>Pulmonary arteries</subject><subject>Rheumatoid arthritis</subject><subject>tnf-alpha inhibitors</subject><subject>toxicity</subject><subject>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><subject>Tumor necrosis factor-TNF</subject><subject>Ultrasonic imaging</subject><issn>2149-2263</issn><issn>2149-2271</issn><issn>2149-2263</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVkUtuFDEQhlsIRKKQKyAL1j341Xb3Bika8QiKxCasW2W7nPHI3R7c7pG4A5fhIpwJDwkRWbmqfvur-stN84bRDZNayndXM5QUv2whu5DihlM2bJRmXD5rzjmTQ8u5Zs8fYyXOmstl2VNKmRY9Y-plcyYYV1Ipet78vMXpkDLkHySiL-SIc8nBrhEygWUJSyEOj8Ei8SkTm6ZDxIIko01HrI98TlPNarwEE5GAXau8Q8iFeAhxzUjciqQkUtapIma0OVVuVW1Juf39i4R5F0yoyavmhYe44OXDedF8-_jhdvu5vfn66Xp7ddM6wXVpJRjvGLeu66B3veodVdAJkB6GAbuTMWCcGtR9708-ey-YEq4XzKHlRlw01_dcl2A_HnKYqv8xQRj_FlK-G-v8wUYcVdcj75iR3KAUZgBDqUQqtXbUa80q6_0967CaCZ097Q_iE-hTZQ678S4dxzqW4IxXwNsHQE7fV1zKuE9rnqv_kfNOq4FL2tVbr_9v88j_95PiD3xfqbU</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Soucy-Giguere, Marie-Camille</creator><creator>Charbonneau, Éric</creator><creator>Cinq Mars, Alexandre</creator><creator>Dubois, Michelle</creator><creator>Sénéchal, Mario</creator><general>Kare Publishing</general><general>KARE Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190701</creationdate><title>Temporary left ventricular assist device for complete recovery from reversible acute heart failure due to tumor necrosis factor-α inhibitor</title><author>Soucy-Giguere, Marie-Camille ; Charbonneau, Éric ; Cinq Mars, Alexandre ; Dubois, Michelle ; Sénéchal, Mario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d327t-4abfd12cd55a8d868d06a53a4fa99e54660a120be788f64668f3163d831dec2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Arthritis - drug therapy</topic><topic>Arthritis - etiology</topic><topic>Biopsy</topic><topic>Blood pressure</topic><topic>Cardiac arrhythmia</topic><topic>Cardiology</topic><topic>Cardiomyocytes</topic><topic>Cardiomyopathy</topic><topic>Cardiomyopathy, Dilated - complications</topic><topic>Cardiomyopathy, Dilated - diagnosis</topic><topic>Cardiomyopathy, Dilated - drug therapy</topic><topic>Cardiotonic Agents - therapeutic use</topic><topic>Case Reports</topic><topic>Clinical deterioration</topic><topic>Crohn Disease - complications</topic><topic>Crohn's disease</topic><topic>Ejection fraction</topic><topic>Electrocardiography</topic><topic>Etanercept - therapeutic use</topic><topic>Family medical history</topic><topic>Female</topic><topic>Furosemide - therapeutic use</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Heart Failure - chemically induced</topic><topic>Heart Failure - therapy</topic><topic>Heart-Assist Devices</topic><topic>Humans</topic><topic>Infliximab - adverse effects</topic><topic>Infliximab - therapeutic use</topic><topic>lvad</topic><topic>Milrinone - therapeutic use</topic><topic>Monoclonal antibodies</topic><topic>Necrosis</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Patients</topic><topic>Pulmonary arteries</topic><topic>Rheumatoid arthritis</topic><topic>tnf-alpha inhibitors</topic><topic>toxicity</topic><topic>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</topic><topic>Tumor necrosis factor-TNF</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soucy-Giguere, Marie-Camille</creatorcontrib><creatorcontrib>Charbonneau, Éric</creatorcontrib><creatorcontrib>Cinq Mars, Alexandre</creatorcontrib><creatorcontrib>Dubois, Michelle</creatorcontrib><creatorcontrib>Sénéchal, Mario</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library (ProQuest Database)</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Anatolian journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soucy-Giguere, Marie-Camille</au><au>Charbonneau, Éric</au><au>Cinq Mars, Alexandre</au><au>Dubois, Michelle</au><au>Sénéchal, Mario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Temporary left ventricular assist device for complete recovery from reversible acute heart failure due to tumor necrosis factor-α inhibitor</atitle><jtitle>Anatolian journal of cardiology</jtitle><addtitle>Anatol J Cardiol</addtitle><date>2019-07-01</date><risdate>2019</risdate><volume>22</volume><issue>1</issue><spage>46</spage><epage>48</epage><pages>46-48</pages><issn>2149-2263</issn><eissn>2149-2271</eissn><eissn>2149-2263</eissn><abstract>We present the case of a 38-year-old woman with symptoms of acute heart failure (HF). In the previous months, she received tumor necrosis factor (TNF)-α inhibitors for the treatment of arthritis secondary to Crohn’s disease. She initially received etanercept (Enbrel) for nearly 1 year and subsequently received infliximab (Remicade) for 6 months. Echocardiograms following the etanercept therapy were normal. Since her disease did not respond well to etanercept, she received 16 treatments of infliximab, at the end of which HF symptoms developed, with rapid clinical deterioration. Her echocardiogram demonstrated dilated cardiomyopathy with severe biventricular dysfunction and left ventricular ejection fraction (LVEF) and right ventricular ejection fraction (RVEF) &lt;20% with severe functional mitral and tricuspid regurgitation. Her extensive diagnostic work-up, including pathological examination of endomyocardial biopsy, was normal. Despite optimal treatment of HF, her status did not improve, and a left ventricular assist device (LVAD, HeartMate II) was implanted. The evolution was unremarkable, and she rapidly recovered in the following months, with LVEF reaching ≥45%. Based on the patient’s clinical improvement and LVEF recuperation, LVAD was removed. Her functional status and LVEF remained stable after LVAD explantation. Therefore, the very probable etiology of the precipitated HF was infliximab toxicity.</abstract><cop>Turkey</cop><pub>Kare Publishing</pub><pmid>31264660</pmid><doi>10.14744/AnatolJCardiol.2019.67124</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2149-2263
ispartof Anatolian journal of cardiology, 2019-07, Vol.22 (1), p.46-48
issn 2149-2263
2149-2271
2149-2263
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_658e251b42be43b9ab004e0477d0f771
source Publicly Available Content (ProQuest); PubMed Central
subjects Adult
Arthritis - drug therapy
Arthritis - etiology
Biopsy
Blood pressure
Cardiac arrhythmia
Cardiology
Cardiomyocytes
Cardiomyopathy
Cardiomyopathy, Dilated - complications
Cardiomyopathy, Dilated - diagnosis
Cardiomyopathy, Dilated - drug therapy
Cardiotonic Agents - therapeutic use
Case Reports
Clinical deterioration
Crohn Disease - complications
Crohn's disease
Ejection fraction
Electrocardiography
Etanercept - therapeutic use
Family medical history
Female
Furosemide - therapeutic use
Heart attacks
Heart failure
Heart Failure - chemically induced
Heart Failure - therapy
Heart-Assist Devices
Humans
Infliximab - adverse effects
Infliximab - therapeutic use
lvad
Milrinone - therapeutic use
Monoclonal antibodies
Necrosis
NMR
Nuclear magnetic resonance
Patients
Pulmonary arteries
Rheumatoid arthritis
tnf-alpha inhibitors
toxicity
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor necrosis factor-TNF
Ultrasonic imaging
title Temporary left ventricular assist device for complete recovery from reversible acute heart failure due to tumor necrosis factor-α inhibitor
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A31%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Temporary%20left%20ventricular%20assist%20device%20for%20complete%20recovery%20from%20reversible%20acute%20heart%20failure%20due%20to%20tumor%20necrosis%20factor-%CE%B1%20inhibitor&rft.jtitle=Anatolian%20journal%20of%20cardiology&rft.au=Soucy-Giguere,%20Marie-Camille&rft.date=2019-07-01&rft.volume=22&rft.issue=1&rft.spage=46&rft.epage=48&rft.pages=46-48&rft.issn=2149-2263&rft.eissn=2149-2271&rft_id=info:doi/10.14744/AnatolJCardiol.2019.67124&rft_dat=%3Cproquest_doaj_%3E2257692405%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d327t-4abfd12cd55a8d868d06a53a4fa99e54660a120be788f64668f3163d831dec2b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2257692405&rft_id=info:pmid/31264660&rfr_iscdi=true